Systematic review of statistical methods used in molecular marker studies in cancer
Open Access
Abstract
BACKGROUND.: There is wide interest in the use of molecular markers for the early detection of cancer, the prediction of disease outcome, and the selection of patients for chemotherapy. Despite significant and increasing research activity, to the authors' knowledge only a small number of molecular markers have been successfully integrated into clinical practice. In the current study, the experimental designs and statistical methods used in contemporary molecular marker studies are reviewed, particularly with respect to whether these evaluated a marker's clinical value.METHODS.: MEDLINE was searched for studies that analyzed an association between a cancer outcome and a marker involving chemical analysis of body fluid or tissue. For each article, data were extracted regarding patients, markers, type of statistical analysis, and principal results.RESULTS.: The 129 articles eligible for analysis included a very large variety of molecular markers; the total number of markers was larger than the number of articles. Only a minority of articles (47 articles; 36%) incorporated multivariate modeling in which the marker was added to standard clinical variables, and only a very small minority had any measure of predictive accuracy (14 articles; 11%). No article used decision analytic methods or experimentally evaluated the clinical value of a marker. Correction for overfit was also rare (3 articles).CONCLUSIONS.: Statistical methods in molecular marker research have not focused on the clinical value of a marker. Attention to sound statistical practice, in particular the use of statistical approaches that provide clinically relevant information, will help maximize the promise of molecular markers for care of the cancer patient. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Decision Curve Analysis: A DiscussionMedical Decision Making, 2007
- Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 YearsJournal of Clinical Oncology, 2007
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Biomarkers in Cancer Staging, Prognosis and Treatment SelectionNature Reviews Cancer, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Outcome Prediction and the Future of the TNM Staging SystemJNCI: Journal of the National Cancer Institute, 2004
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon CancerNew England Journal of Medicine, 2001